A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion

Всесторонний обзор исследований II/III фазы при остеоартрите: экспертное мнение
Liyang Pan, Lydia Nagib, Sujata Ganguly, Arumugam Moorthy, Hasan Tahir
2024-08-01

MRI-proven synovitisSprifermindisease-modifying osteoarthritis drugsosteoarthritisphase II/III clinical trials
INTRODUCTION: Osteoarthritis (OA) is a chronic, degenerative, and debilitating disease associated with significant long-term morbidity and disability. The pathogenesis of OA is not completely understood but involves an interplay between environmental risk factors, joint mechanics, abnormal pain pathways and upregulation of inflammatory signaling pathways. Current therapeutic options for patients are limited to conservative management, minimal pharmacological options or surgical management, with significant caveats to all approaches. AREAS COVERED: In this review, we have set out to investigate current phase II/III clinical trials by undertaking a PubMed search. Examined clinical trials have explored a myriad of potential therapeutics from conventional disease-modifying anti-rheumatic drugs and biologics usually used in the treatment of inflammatory arthritides, to more novel approaches targeting inflammatory pathways implicated in OA, cartilage degeneration or pain pathways. EXPERT OPINION: Unfortunately, most completed phase II/III clinical trials have shown little impact on patient pain scores, with the exception of the traditional DMARD methotrexate and Sprifermin. Methotrexate has been shown to be beneficial when used in the correct patient cohort (MRI proven synovitis). Sprifermin has the longest follow-up data of 5 years and has been shown to reduce loss of MRI-measured cartilage thickness and pain scores.
1
Current osteoarthritis treatments remain limited by substantial caveats across conservative, pharmacological, and surgical approaches.
2
Methotrexate showed benefit in a selected osteoarthritis cohort with MRI-confirmed synovitis.
3
Most completed phase II/III trials produced little improvement in patient-reported pain scores.
4
Sprifermin demonstrated reduced loss of MRI-measured cartilage thickness and reduced pain scores, with follow-up extending to five years.
5
The review evaluates phase II/III osteoarthritis trials spanning conventional DMARDs, biologics, inflammatory-pathway targets, cartilage-directed therapies, and pain-pathway interventions.

Phase II/III clinical trials of therapies for osteoarthritis

Therapeutic efficacy for osteoarthritis pain, synovitis, and cartilage degeneration

Publication Details
Publication Date
2024-08-01
Journal
Publisher
ISSN
Cited by
5
Access Type
Author Information
Authors
Liyang Pan
Lydia Nagib
Sujata Ganguly
Arumugam Moorthy
Hasan Tahir
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%